Summary: The objective of this study was to evaluate the Bayesian predictability of vancomycin (VCM) pharmacokinetics in Japanese pediatric patients using one-compartment population pharmacokinetic (PPK) parameters, which we reported previously. The validity of the PPK model was evaluated by bootstrap method and cross validation method, and the Bayesian predictive performance was examined. The predictive performance of the PPK model for premature patients was also examined.
Introduction
Vancomycin (VCM) is an eŠective glycopeptide antibiotic against gram-positive infections and has been widely used especially to treat patients with methicillinresistant Staphylococcus aureus (MRSA). 1, 2) The clinical pharmacokinetics of VCM has been reviewed for adult [3] [4] [5] and pediatric patients, 6, 7) and dosage regimens have been discussed for the optimization of VCM therapy. The pharmacokinetic proˆle of VCM is known to diŠer between pediatric and adult patients because of diŠerences in body size and functions of the eliminating organ(s). 6, 7) To understand the pharmacokinetic properties of VCM in pediatric patients, we previously developed a population pharmacokinetic (PPK) model for Japanese pediatric patients. 8) The major side eŠect of VCM in adult patients is nephrotoxicity, and its occurrence is related to the high trough concentration of VCM. [9] [10] [11] Although nephrotoxicity related to drug concentration in pediatric patients has not been clariˆed, [12] [13] [14] guidelines for the recommended therapeutic window for adult patients are usually applied for pediatric patients to propose regimens. What is needed is a better understanding of the pharmacokinetic proˆles of pediatric patients, as well as adult patients, for adequate clinical usage of VCM.
VCM is mainly eliminated via the kidney by glomerularˆltration, 4) and insu‹cient renal function in a patient can lead to a long elimination half-life and a high serum level of VCM, consequently increasing the risk of nephrotoxicity. In order to reduce the possibility of side eŠects and also to maintain an eŠective drug concentration, recommended therapeutic windows have been reported: a peak (1 to 2 hours after the end of infusion) concentration of below 25-40 mg W mL and a trough concentration of below 10 mg W mL. 15) To control VCM concentration in these windows, therapeutic drug monitoring (TDM) is useful and allows the planning of individual optimal VCM dosage regimens. In TDM, because little drug concentration data are usually available, the Bayesian method is applied in combination with measured concentration data and PPK parameters to predict the drug concentration proˆle for each individual, 16 ) using a sophisticated computer program. 17, 18) We have already reported the PPK parameters of VCM for Japanese adult and pediatric patients, 8, 19) and also developed a computer program to perform the Bayesian prediction. 20) When a prediction method such as the Bayesian method is applied, it is important to know the predictability of the drug concentration and individual pharmacokinetic parameters because the predictability depends on the PPK parameters and also on the sampling time. [21] [22] [23] We have already evaluated the predictive performance of PPK parameters of VCM based on a two-compartment model in Japanese adult patients. 24) The pharmacokinetic variability of VCM in pediatric patients, especially neonates and premature neonates, is generally large because of the changes in body water volume and diŠerences in the extent of renal function maturation. 6, 7) Thus, it is recommended that the VCM dosage in pediatric patients be individually adjusted using TDM. For this purpose, it is important to know the validity and the Bayesian predictive performance of the PPK parameters obtained for Japanese pediatric patients.
As internal data, we used the same data as those used for the PPK model development because no external data for pediatric patients were available. We applied two validation methods to evaluate the parameter stability and the robustness of the model. One was a bootstrap method 25) to evaluate the stability of the PPK parameters, and the other was a cross validation method 26) to conˆrm the robustness of the model. We also examined the Bayesian predictive performance of the PPK parameters. The Bayesian method was incorporated into the cross validation method as Ishibashi et al. had done previously. 27) In addition, serum concentration data reported for premature patients 28) were used as external data to evaluate the applicability of our PPK parameters for premature patients. Also, a theoretical approach using a simulation technique was performed to evaluate the in‰uence of sampling time on the predictive performance.
Methods
Population pharmacokinetic parameters: PPK parameters reported for Japanese pediatric patients based on a one-compartment model 8) were evaluated in this study. Theˆnal PPK model is referred to as thè reported' PPK model in this paper. The reported PPK parameters and the background of the population are summarized in Table 1 .
Validation of the reported PPK model and Bayesian predictability: Validation of the reported PPK model was performed by the bootstrap method and the cross validation method using internal data. The predictive performance of the Bayesian method was also evaluated as a part of the cross validation approach.
The bootstrap method 25) was used to evaluate the stability and conˆrm the robustness of the reported PPK model. One thousand bootstrap data sets were generated based on the reported PPK parameters, and the same model wasˆtted to each of the 1000 data sets. The average (mean), standard error (S.E.) and 95z conˆdence interval (95z C.I.) for estimates of the population mean and variance parameters were calculated and compared with the reported parameter estimates.
The cross validation method 26) was also applied to evaluate the robustness of the reported PPK model. The data for all 49 patients were randomly divided into 10 data sets, which consisted of data for about 10z patients of all patients without overlap. 10 subsets which consisted of one data set (10z patients) and the remaining nine data sets (90z patients) were generated using these 10 data sets. For each 10 subsets, the same model wasˆtted to the data for 90z patients, and the parameter estimates for 10 subsets were obtained. Next, Jackknife estimates for the mean, S.E. and 95z C.I. for each parameter were calculated and compared with those for the reported PPK parameters to conˆrm the robustness of theˆnal model. 26, 27) The predictive performance in the Bayesian method was examined by assuming a one-point Bayesian prediction, which predicts serum concentrations at designated times using one point of serum concentration data for a patient. The Bayesian prediction was performed using each PPK parameter set obtained from each 10 subsets for the rest of the data in each of the 10 subsets (i.e. each 10z of all patients' data). The observed data from 0 to 3 hours after the end of intravenous infusion were chosen as`peak' concentrations and those from 1 to 0 hour prior to the start of the next infusion were selected as`trough' concentrations. For these data, the Bayesian predicted values were compared with the observed data. For all 49 patients, 27 patients with both`peak' and trough' data during multiple dosing were used for this evaluation. For the Bayesian prediction, the peak or the trough concentration data on a day were used to predict the other peak and trough concentrations on subsequent days, and the predicted and observed concentrations at a corresponding time were compared for the predictive performance.
In order to examine the applicability of the reported PPK parameters to premature patients, we evaluated the Bayesian predictive performance using the serum concentration data reported for 10 Japanese premature patients.
28) The patient characteristics are summarized as follows (mean±S.D. [minimum-maximum]): gestational age 31.4±5.5 [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] (weeks), postnatal age at the start of VCM dose 19.6±9.5 (days), and body weight 1081.5±563.8 [442-2060] (g). VCM concentrations were measured at the start of infusion (used as`trough' data) and 2 hours after the end of infusion (used as`peak' data) on the 2nd and 5th dosing. Dose and dosing interval varied among the patients. 28) For the Bayesian prediction, the observed peak or trough data on the 2nd dosing were used to predict the peak and trough concentrations on the 5th dosing.
The predictive performance was evaluated by comparing the observed and Bayesian predicted concentrations, using`mean prediction error (ME)' as a measure of bias and`root mean squared error (RMSE)' as a measure of precision 29) given by Eqs. (1) and (2), respectively.
N is the number of data points, Cobs,j and Cpred,j are the j-th observed and predicted concentrations, respectively. Although the indices, ME and RMSE, should be calculated using log-transformed concentrations as the reported PPK model assumes a log-normal distribution for intra-individual variability, in this paper, we deˆne them by Eqs. (1) and (2), because we thought that evaluation of absolute prediction error is more practical and useful when considering a variable degree of concentrations for clinical use. Theoretical evaluation of predictive performance: In order to theoretically assess the predictive performance and determine the optimal sampling time for the Bayesian prediction using the reported PPK parameters, we evaluated the prediction error of pharmacokinetic parameters and ME and RMSE of VCM concentrations using a simulated data set. Hypothetical serum VCM concentration proˆles for 500 subjects were simulated based on the PPK parameters, by assuming a single infusion of 15 mg W kg for 1 hour. The age of each subject was randomly generated from a uniform distribution U [0. 5, 15] . The body weight of each subject was not generated, because the amount of the dose and both PPK parameters of CL and Vd are all given with respect to body weight. Individual CL and Vd were generated from a log-normal distribution with the PPK mean value as the mean and inter-individual variability as the variance. The sampling time points were 1, 2, 3, 4, 6, 8 and 12 hours after the start of infusion.
Using the simulated concentration data at any one of the sampling points for each subject, serum concentrations at the peak and the trough were predicted by the Bayesian method to evaluate the eŠect of sampling time on the predictive performance using ME and RMSE. In the simulation study, the peak and the trough were deˆned as the point at 2 and 8 hours after the start of infusion (i.e. at 1 and 7 hours after the end of infusion), respectively.
In the simulation study, the predictive performance of the pharmacokinetic parameters such as CL and Vd by the Bayesian method was evaluated based on the prediction error (PE) calculated by Eq. (3), PEjk(z)＝ Ppop,jk-Ppred,jk Ppop,jk ×100
where Ppop,jk is an individual pharmacokinetic parameter predicted by population mean parameters and individual covariates, and Ppred,jk is an individually predicted pharmacokinetic parameter by the Bayesian method, for the k-th pharmacokinetic parameter in the j-th subject. Mean and S.D. values were obtained from PE jk calculated for all subjects. Software: A computer program for nonlinear mixed eŠect modeling, NONMEM Version V, 30, 31) was used for the Bayesian prediction with a posthoc option, with a FORTRAN 77 compiler (Sun-Pro) on a Soralis 7 UNIX operation system (Sun Microsystems, U.S.A.). Generation of the simulation data sets was also performed by NONMEM.
Results and Discussion
The results of the validation by the bootstrap method and the cross validation method are summarized in Table 2 . The mean values of the bootstrap estimates for each PPK parameter were comparable with the reported PPK parameter estimates. The mean, S.E. and 95z C.I. for the Jackknife estimates of each parameter by the cross validation method are similar to those obtained by the bootstrap method and the Jackknife mean values are almost comparable with those from the Fig. 2 . Correlation between observed and predicted VCM concentrations by the Bayesian method based on cross validation. Open circles: predicted peak using peak data point, open triangles: predicted trough using peak data point, closed circles: predicted peak using trough data point, closed triangles: predicted trough using trough data point. The dotted line represents identity. reported PPK model. Figure 1 shows the plots of the mean parameter estimates for 10 subsets in the cross validation. The values for each subset are within the range of ±1 S.E. of the reported PPK parameters, thus conˆrming the robustness and stability of the reported PPK model. The Bayesian predictability was also examined using the cross validation data sets. Table 3 shows the ME and RMSE values for possible peak W trough combinations from the Bayesian prediction. The values of ME were 1.84 and -0.68 mg W mL when the peak data for peak prediction and the trough data for trough prediction were used, respectively. When the trough concentration was predicted using other trough data, the ME seems to be enough small for practical use. When peak data were used for trough prediction or trough data for peak prediction, the ME values were -1.00 and 2.05 mg W mL, respectively. The RMSE are around 10 mg W mL for peak prediction and are smaller for trough prediction. Figure 2 shows the correlation between the observed and the predicted concentrations for each patient for all combinations in Table 3 . When the observed values were greater than 40 mg W mL, the reported PPK parameter estimates tended to underestimate VCM concentrations. A possible explanation for this is the limitation of using a one-compartment model, i.e. the model can not accurately predict higher concentration data around the peak, which may actually be in the distribution phase. Thus, the predictive performance for the trough concentration was generally better than for the peak concentration ( Table 3) . We therefore conclude that it is better to use trough data for predicting the trough concentration. Considering this and the general understanding that nephrotoxicity is related to the trough concentration, [9] [10] [11] we suggest that sampling at the trough is preferable for TDM for pediatric patients. Table 4 shows the predictive performance for the premature patients. Figure 3 shows the correlation between the observed and the predicted concentrations for each combination of each patient. In some patients, there was a considerably large deviation, suggesting that the reported PPK model does not seem to have good applicability for premature patients. One possible reason for less predictability of the reported PPK model for premature patients is a diŠerence in the pharmacokinetic properties of VCM between pediatric and premature patients. Therefore, the reported PPK model could not adequately explain the subsequent pharmacokinetic proˆles in the premature patients, although some were included in the population data. It is generally said that premature patients have a larger Vd and lower CL because of a larger amount of body water and incomplete maturation of the renal function compared with infants, children and adults. 7) Another reason may be the existence of an unincorporated covariate for the inter-individual pharmacokinetic variability. The CL of VCM in premature patients has been reported to depend on their postconceptional age, 32) but only the postnatal age is incorporated for the reported PPK parameters. Still another reason may be that the background of the premature population used in this study 28) was to some extent diŠerent from that of the population used for the development of the reported PPK model. 8) We also examined the predictive performance of the two-point Bayesian method using both peak and trough concentrations in the internal data. ME and RMSE for the peak prediction were 2.43 mg W mL and 11.24 mg W mL and those for the trough prediction were 0.28 mg W mL and 2.96 mg W mL, respectively. These values were similar to those for the one-point Bayesian method ( Table 3) and no clear improvement of the predictive performance was found. Therefore, it is considered that one sampling point at the trough is su‹cient for prediction.
In the theoretical approach using simulated data, we focused on two predicted time points, peak and trough. Figure 4 shows the ME (Fig. 4(a) ) and RMSE (Fig. 4(b) ) for predicting peak and trough concentrations when data at several diŠerent sampling points were used for the Bayesian method. Regarding ME, peak concentrations tended to be slightly overestimated (less than 0) at all sampling points. However, the ME values are in general small enough for practical use at all sampling points for predicting both peak and trough levels. As shown in Fig. 4(b) , the RMSE values for peak prediction are almost independent of the sampling times for the Bayesian estimation, and the predictive performance does not seem to be good even when any sampling points were used for the peak prediction. On the other hand, for the trough prediction, RMSE depended on the sampling times and a later sampling time tended to give smaller RMSE. Figure 5 shows PE values for the Bayesian estimates of CL and Vd obtained from the simulated data. The plots illustrated that the PE of Vd is almost independent of the sampling time, but in the case of CL, PE is smaller at a later sampling time. Similarˆndings have been presented in a previous paper, 21) and our results coincided well with them. The time dependence in RMSE observed for the trough prediction (Fig. 4(b) ) may be related to the time dependence of the predictability for CL shown in Fig. 5(a) , as the trough concentration is more informative for CL than other sampling points. Therefore, the trough concentration is considered to be appropriate for predicting trough concentration.
Some reports have appeared on the predictive performance of the Bayesian method for pediatric patients. Rodvold et al. showed that predictive performance is not necessarily acceptable when there is a long period between the times of the observed and predicted concentrations. 33) This suggests that the most up-to-date data should be used for the Bayesian prediction, especially for pediatric patients who usually display large intraindividual pharmacokinetic variability. Wrishko et al. also evaluated the predictive performance of VCM concentration in pediatric patients and showed that trough sampling alone could provide clinically acceptable predictions of VCM concentrations at other sam- pling points. 34) They also showed that a later sampling point improved the relative accuracy and precision of trough prediction. Theseˆndings coincide with our present results, although the compartment model used in each study is diŠerent.
In conclusion, the reported PPK model for pediatric patients was validated and it was conˆrmed that the Bayesian predictability, especially for the trough concentration, is acceptable, with support from the simulation study. However, the reported PPK model does not seem to have good applicability for premature patients. For pediatric patients, we recommend measuring the trough concentration as theˆrst choice for an optimal sampling point for the Bayesian prediction.
